Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194089 | 0.89 | GRM5 (0.81) | GRM5NPC1RAB9AKDM4EGAA | |
| SCHEMBL1982589 | 0.83 | GRM5 (0.72) | GRM5NPC1RAB9AKDM4EMAPT | |
| SCHEMBL6928562 | 0.80 | GRM5 (1.00) | GRM5MAPT | |
| SCHEMBL6918727 | 0.80 | GRM5 (0.77) | GRM5NPC1RAB9AKDM4EMAPT | |
| SCHEMBL6927216 | 0.79 | GRM5 (1.00) | GRM5CYP3A4 | |
| SCHEMBL1979922 | 0.77 | GRM5 (1.00) | GRM5NPC1RAB9AKDM4EMAPT | |
| SCHEMBL6928965 | 0.76 | GRM5 (0.74) | GRM5NPC1RAB9A | |
| SCHEMBL6928710 | 0.76 | GRM5 (0.80) | GRM5CYP3A4 | |
| SCHEMBL6918571 | 0.76 | GRM5 (0.68) | GRM5NPC1RAB9AKDM4EMAPT | |
| SCHEMBL6918545 | 0.75 | GRM5 (0.60) | GRM5NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477629-B1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | UNIV VANDERBILT (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| WO-2011035186-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | GRM5 1/4885NPC1 2663/4885RAB9A 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.